Hot Investor Mandate 3: Hedge Fund Bets Big on Late-Stage Therapeutic and Genomic Platforms

4 May

A hedge fund sponsor with offices in New York, Hong Kong and London currently manages a total of over $30 billion in total. The firm invests primarily in public and private equity securities from a wide range of industries globally. The firm prefers to participate in a financial round of at least $40 million, and has no hard stops on phase of development. The group has the potential of allocating $100 million in equity over the life of investment in companies with at least $400 million valuation.

The firm invests across several industry sectors. In life sciences, the firm is agnostic to subsectors and therapeutic areas but is currently interested in genomics and biotech therapeutics. The firm looks for late stage platform technologies with significant market potential, and rarely invest in companies with a single therapeutic asset.

The firm is seeking competent and experienced management teams with proven business model.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: